logo
menu
배경이미지
01About us
Spin offCollaborationCILoacation
02Platforms
Ocular ImplantsMicroarray Patches
03Pipelines
SMO SeriesSMM SeriesSMZ Series
04Facilities
SMO LineSMM Line1st Site2nd Site
05Business
Business ModelCDMO Business
06News
NoticeIRPR
07Contact us
call@sminnovation.com
Home    >    Pipelines    >    SMM SeriesSMM Series

SMM

SMM1
SMM2
SMM3
SMM4
SMM1 image 1
SMM1 image 2

SMM1 Information

Indication
Osteoporosis
Active Ingredient
Teriparatide
Administration Site
Transdemal Administration
Competing Products
Forteo / Lilly
Milestones
milestones
* The release schedule of SMM1, SMM2, SMM3 and SMM4 are subject to change depending on the patent situation of each country
footer-logo
CEO : Jinha Park
Company : SANGMYUNG innovation Co., Ltd.
T : +82 2 3489 6100
Head Office : 2-27, Yeongmun-ro, Cheoin-gu, Yongin-si, Gyeonggi-do, Republic of Korea
Branch Office : 42, Seocho-daero 52-gil, Seocho-gu, Seoul, Republic of Korea
Privacy PolicyCopyright © SANGMYUNG innovation